Zanidatamab

Action and Spectrum

Actions and Spectrum: 

Zanidatamab is a humanized and bispecific antibody which targets HER2 non-overlapping domains. 

The HER2-targeted therapies improve outcomes in breast, gastric, and gynaecological cancers. 

Drug Interaction

Adverse Reaction

Frequency not defined  

Diarrhoea  

Black Box Warning

Black box warning:

None

Contraindication / Caution

Contraindications/caution:

None

Pregnancy / Lactation

Pregnancy Warnings: 

Pregnancy category: N/A 

Lactation: Excretion of the drug into the human breast milk is unknown 

Pregnancy categories: 

• Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester. 
• Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women. 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women. 
• Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology  

It is bispecific antibody which binds to two non-overlapping HER2 epitopes which result in dual HER2 signal blockade.
It increases HER2 protein binding and removal which provides potent effector function. 

Pharmacodynamics  

Zanidatamab has greater in-vitro and in-vivo anti-tumour activity across HER2-overexpressing tumour cell types and has potential clinical activity against low HER2 expression tumours.

Pharmacokinetics: 

Zanidatamab continues in ongoing studies thus data on ADME is not available.  

Adminstartion

Administration: 

The drug is administered intravenously.  

Patient Information Leaflet

Patient information leaflet 

Generic Name: zanidatamab 

Why do we use zanidatamab? 

Zanidatamab is studied to evaluate the safety and anti-tumour activity of solid tumours. 

Zanidatamab targets HER2 i.e., human epidermal growth factor receptor 2, which is beneficial in some cancers such as breast, gastric, and gastroesophageal.